Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 12/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 12/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577936 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| Hydrochloric Acid SCHEMBL30827007 | 0.98 | IDO1 (0.42) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| Hydrochloric Acid SCHEMBL23246355 | 0.98 | IDO1 (0.42) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| Hydrochloric Acid SCHEMBL23246354 | 0.98 | IDO1 (0.42) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL4234796 | 0.87 | IDO1 (0.51) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL14120782 | 0.87 | IDO1 (0.51) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL29656429 | 0.87 | IDO1 (0.51) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL4550765 | 0.87 | IDO1 (0.51) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL29845425 | 0.87 | IDO1 (0.51) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| Hydrochloric Acid SCHEMBL25358651 | 0.85 | IDO1 (0.54) | CYP1A2CYP3A4CYP2D6NFKB1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| CN-120058795-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058797-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058796-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-115461342-B | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-4472974-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Schrödinger, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118974038-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2022161461-A1 | SOS1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022161461-A1 | SOS1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022156792-A1 | HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-07-28 | — | — | WO | disclosed |
| CN-114539245-A | Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | CYP1A2 1336/4885CYP3A4 2154/4885CYP2D6 1254/4885 |
| US-20240109891-A1 | NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | CYP1A2 3756/4885CYP3A4 3951/4885CYP2D6 3912/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | CYP1A2 1427/4885CYP3A4 2277/4885CYP2D6 1324/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | CYP1A2 910/4885CYP3A4 1541/4885CYP2D6 871/4885 |
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | CYP1A2 3877/4885CYP3A4 3861/4885CYP2D6 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.